Peter Heerma's most recent trade in Travere Therapeutics Inc was a trade of 4,920 Performance-based restricted stock units done . Disclosure was reported to the exchange on May 2, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Travere Therapeutics Inc | Peter Heerma | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2025 | 4,920 | 4,920 | - | - | Performance-based restricted stock units | |
| Travere Therapeutics Inc | Peter Heerma | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2025 | 4,920 | 129,986 (0%) | 0% | - | Common Stock | |
| Travere Therapeutics Inc | Peter Heerma | CHIEF COMMERCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 21.05 per share. | 02 May 2025 | 1,771 | 128,215 (0%) | 0% | 21.1 | 37,280 | Common Stock |
| Travere Therapeutics Inc | Peter Heerma | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2025 | 8,000 | 0 | - | - | Performance-based restricted stock units | |
| Travere Therapeutics Inc | Peter Heerma | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2025 | 8,000 | 130,708 (0%) | 0% | - | Common Stock | |
| Travere Therapeutics Inc | Peter Heerma | CHIEF COMMERCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 10 Feb 2025 | 3,074 | 127,634 (0%) | 0% | 25 | 76,850 | Common Stock |
| Travere Therapeutics Inc | Peter Heerma | CHIEF COMMERCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 23.53 per share. | 10 Feb 2025 | 2,568 | 125,066 (0%) | 0% | 23.5 | 60,426 | Common Stock |
| Travere Therapeutics Inc | Peter Heerma | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 58,000 | 58,000 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Peter Heerma | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 21,500 | 127,874 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Peter Heerma | CHIEF COMMERCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 20.12 per share. | 31 Jan 2025 | 5,166 | 122,708 (0%) | 0% | 20.1 | 103,940 | Common Stock |
| Travere Therapeutics Inc | Peter Heerma | CHIEF COMMERCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 18.94 per share. | 22 Jan 2025 | 1,584 | 106,374 (0%) | 0% | 18.9 | 30,002 | Common Stock |
| Travere Therapeutics Inc | Peter Heerma | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Sep 2024 | 6,750 | 110,149 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Peter Heerma | CHIEF COMMERCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 11.52 per share. | 05 Sep 2024 | 2,191 | 107,958 (0%) | 0% | 11.5 | 25,240 | Common Stock |
| Travere Therapeutics Inc | Peter Heerma | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 65,000 | 65,000 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Heerma Peter | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 25,000 | 103,698 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Peter Heerma | CHIEF COMMERCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 8.53 per share. | 31 Jan 2024 | 4,195 | 99,503 (0%) | 0% | 8.5 | 35,789 | Common Stock |
| Travere Therapeutics Inc | Peter Heerma | CHIEF COMMERCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 9.07 per share. | 23 Jan 2024 | 1,559 | 78,698 (0%) | 0% | 9.1 | 14,138 | Common Stock |
| Travere Therapeutics Inc | Peter Heerma | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 54,500 | 54,500 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Peter Heerma | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 20,250 | 83,848 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Peter Heerma | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 6,750 | 6,750 | - | - | Performance-based restricted stock units | |
| Travere Therapeutics Inc | Peter Heerma | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 21.75 per share. | 31 Jan 2023 | 1,779 | 82,069 (0%) | 0% | 21.8 | 38,697 | Common Stock |
| Travere Therapeutics Inc | Peter Heerma | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 21.90 per share. | 24 Jan 2023 | 1,550 | 63,598 (0%) | 0% | 21.9 | 33,952 | Common Stock |
| Travere Therapeutics Inc | Peter Heerma | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.68 per share. | 04 Oct 2022 | 3,042 | 65,148 (0%) | 0% | 25.7 | 78,119 | Common Stock |
| Travere Therapeutics Inc | Peter Heerma | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 39,360 | 39,360 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Peter Heerma | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 9,840 | 68,422 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Peter Heerma | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 9,840 | 9,840 | - | - | Performance-based restricted stock units | |
| Travere Therapeutics Inc | Peter Heerma | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 8,000 | 8,000 | - | - | Performance-based restricted stock units | |
| Travere Therapeutics Inc | Peter Heerma | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 27.40 per share. | 31 Jan 2022 | 1,125 | 67,297 (0%) | 0% | 27.4 | 30,825 | Common Stock |
| Travere Therapeutics Inc | Peter Heerma | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 24.98 per share. | 24 Jan 2022 | 1,875 | 58,582 (0%) | 0% | 25.0 | 46,838 | Common Stock |
| Travere Therapeutics Inc | Peter Heerma | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 24.77 per share. | 04 Oct 2021 | 3,058 | 60,457 (0%) | 0% | 24.8 | 75,746 | Common Stock |
| Travere Therapeutics Inc | Peter Heerma | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2021 | 4,500 | 64,922 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Peter Heerma | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 17.12 per share. | 13 Aug 2021 | 1,407 | 63,515 (0%) | 0% | 17.1 | 24,086 | Common Stock |
| Travere Therapeutics Inc | Peter Heerma | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 31.41 per share. | 05 Feb 2021 | 1,125 | 60,469 (0%) | 0% | 31.4 | 35,336 | Common Stock |
| Travere Therapeutics Inc | Peter Heerma | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 31.58 per share. | 05 Feb 2021 | 1,125 | 59,344 (0%) | 0% | 31.6 | 35,528 | Common Stock |
| Travere Therapeutics Inc | Peter Heerma | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 4,500 | 61,594 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Peter Heerma | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 30.75 per share. | 02 Feb 2021 | 563 | 57,657 (0%) | 0% | 30.7 | 17,312 | Common Stock |
| Travere Therapeutics Inc | Peter Heerma | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 28.91 per share. | 02 Feb 2021 | 563 | 57,094 (0%) | 0% | 28.9 | 16,276 | Common Stock |
| Travere Therapeutics Inc | Peter Heerma | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2021 | 57,500 | 57,500 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Peter Heerma | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2021 | 15,000 | 58,220 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Peter Heerma | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 18.90 per share. | 02 Oct 2020 | 2,188 | 44,517 (0%) | 0% | 18.9 | 41,353 | Common Stock |
| Travere Therapeutics Inc | Peter Heerma | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 19.35 per share. | 02 Oct 2020 | 2,188 | 42,329 (0%) | 0% | 19.4 | 42,338 | Common Stock |